Product image of Juzimette (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Juzimette

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Juzimette (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Juzimette, is a biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycemic control.
GNH India supplies Juzimette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Juzimette combines metformin and sitagliptin to improve glycemic control in type 2 diabetes mellitus.
  • Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels.
  • Adjunct to diet and exercise: enhances overall glycemic management when lifestyle measures alone are insufficient.
  • Combination with other antidiabetics: provides additional glucose reduction when monotherapy does not achieve targets.

How It Works

  • Metformin decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, while sitagliptin inhibits dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels that enhance glucose‑dependent insulin secretion and suppress glucagon release, together producing better blood glucose regulation.

Side Effects

Juzimette may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: loose stools, usually transient.
  • Abdominal discomfort: cramping or bloating.
  • Headache: mild tension‑type headache.
  • Mild hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Metallic taste: occasional altered taste perception.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Severe hypoglycemia: profound low blood glucose requiring assistance.
  • Pancreatitis: acute inflammation of the pancreas.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Allergic reactions: rash, pruritus, or angioedema.
  • Renal impairment: worsening kidney function, especially in dehydration.

Precautions & Warnings

  • Before prescribing Juzimette, clinicians should evaluate patient‑specific factors and monitor for potential complications.
  • Renal function assessment: evaluate eGFR before initiating and periodically thereafter.
  • Liver disease monitoring: avoid in patients with significant hepatic impairment.
  • Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia or severe infection.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk.
  • Drug‑induced hypoglycemia: educate patients on recognizing low‑blood‑glucose symptoms.
  • Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Juzimette can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of hypoglycemia.
  • Iodinated contrast media: may precipitate renal impairment with metformin.
  • Cimetidine: can raise metformin plasma concentrations.
  • Strong CYP3A4 inhibitors: may affect sitagliptin metabolism.
  • Alcohol abuse: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

  • Diuretics: may alter renal clearance of metformin.
  • Beta‑blockers: can mask hypoglycemia symptoms.
  • ACE inhibitors/ARBs: monitor renal function and electrolytes.
  • Warfarin: possible effect on INR, require closer monitoring.
  • Rifampin: may reduce sitagliptin exposure, affecting efficacy.

Frequently Asked Questions

Juzimette is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It combines metformin, which reduces hepatic glucose production, with sitagliptin, which enhances insulin secretion in response to meals, providing a complementary approach to achieve target glycemic levels.

Metformin lowers glucose output from the liver and increases insulin sensitivity in muscle and fat tissue. Sitagliptin blocks the enzyme DPP‑4, raising levels of incretin hormones that stimulate insulin release and suppress glucagon after meals. Together they reduce fasting and post‑prandial blood sugar.

The specific dose of Juzimette is determined by the prescribing healthcare professional based on individual patient factors such as renal function, concomitant medications, and glycemic targets. Patients should follow the exact regimen written on their prescription and not adjust the dose without medical advice.

The safety of Juzimette in pregnancy and lactation has not been fully established. It should only be used if the potential benefits outweigh the possible risks to the fetus or infant, and this decision must be made by a qualified prescriber after careful evaluation.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

Compared with metformin alone, Juzimette adds sitagliptin, offering greater post‑prandial glucose reduction without the weight gain associated with some sulfonylureas. Unlike insulin, it is oral and carries a lower risk of severe hypoglycemia, making it a convenient option for many patients needing combination therapy.

Store Juzimette at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and direct sunlight. Keep the tablet bottle tightly closed and out of reach of children. Do not use the product after the expiration date printed on the label.

Juzimette is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water. Patients must follow the dosing schedule prescribed by their healthcare provider and should not crush or chew the tablet.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and severe hypoglycemia, especially when combined with insulin or sulfonylureas. Pancreatitis and significant renal or hepatic impairment are also rare but critical adverse events that require immediate medical attention.

Juzimette is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, acute or chronic metabolic acidosis, and those with a history of lactic acidosis. It should also be avoided in patients with uncontrolled heart failure or severe liver disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT